

# INSTITUT FÜR PROPHYLAXE & EPIDEMIOLOGIE DER KREISLAUFKRANKHEITEN (IPEK)

DIREKTOR: UNIV.-PROF. DR. CHRISTIAN WEBER

**ANZAHL DER HAUSHALTFINANZIERTEN WISSENSCHAFTLICHE MITARBEITER: 27**

**ANZAHL DER HAUSHALTFINANZIERTEN NICHT-WISSENSCHAFTLICHE MITARBEITER: 21**

**ANZAHL ALLER DRITTMITTELFINANZIERTEN MITARBEITER: 80**

**DRITTMITTELAUSGABEN (IN €):**

	Anzahl Projekte	Ausgaben 2018 laut Verwaltung
DFG	38	3.160.984
BMBF, StMWFK	16	1.179.857
EU	6	966.735
Stiftungen (Humboldt, Fondation Leducq, etc.)	19	340.272
<b>Summe begutachtete externe Drittmittel</b>		<b>5.647.850</b>

	Anzahl Projekte	Ausgaben 2018 laut Verwaltung
FöFoLe	1	25.400
Lebmit (Invest.)	17	25.867
Promotionsstipendien	2	15.081
<b>Summe interne Drittmittel</b>		<b>66.348</b>

<b>Gesamtsumme verausgabte Drittmittel</b>		<b>5.714.198</b>
--	--	------------------

**PUBLIKATIONEN:**

	Anzahl	ungewichteter IF
im WoS gelistete Originalarbeiten	56	520,9
im WoS gelistete Reviews, Editorials	30	233,3
<b>Gesamtsumme</b>	<b>86</b>	<b>754,2</b>

## FORSCHUNGSSCHWERPUNKTE

- Chemokine und Chemokinrezeptoren bei entzündlicher und atherogener Leukozytenrekrutierung
- Versatile Regulation der Atherosklerose durch microRNAs
- Funktion der Neutrophilen und Ihrer Sekretion in frühen Stadien der Atherosklerose
- Rolle von Chemokinen und Chemokin-ähnliche Funktionen von MIF in der Atherosklerose und Restenose
- Struktur und Funktion der Heterooligomerisierung und Proteoglykanbindung von Chemokinen („Interaktom“)
- Signaltransduktion der Integrinregulation in Leukozyten und der endothelialen Aktivierung durch Zytokine
- Junktionale Adhäsionsmoleküle in der transendothelialen Diapedese und der vaskulären Entzündungsreaktion
- Chemokine und ihre Rezeptoren in der myokardialen Ischämie-Reperfusion und bei Myokardinfarkt
- Rolle von Leukozytensubpopulationen (Monozyten, T Zellen, dendritische Zellen, Mastzellen) in der Atherosklerose
- Regulation der Homöostase und Rekrutierung vaskulärer Vorläuferzellen in der Atherosklerose und nach Infarkt
- Physiologie und Pathophysiologie endothelialer Vorläuferzellen in der Endothelregeneration und Risikobestimmung
- Statine zur Prävention der Endotheldysfunktion und miniaturisierte, eluierende Formgedächtnis- und Polymer-Stents
- Intravitalmikroskopie, 2-Photonmikroskopie und Mechanismen der Plaquedestabilisierung
- Transmembranäre Chemokine und proteolytische Spaltung durch ADAM Metalloproteasen
- Rolle des Endocannabinoidsystems in der Atherosklerose und Ischämie/Reperfusion
- Mechanismen von ApoE bei Entzündung, Alzheimer und Atherosklerose
- Neuroimmune Grenzflächen, Innervation und Autoimmunität in der Atherosklerose

## PUBLIKATIONEN

## Originalarbeiten, Reviews, Editorials - gelistet im Web of Science (WoS)

1. Aarts SABM, Reiche ME, den Toom M, Beckers L, Gijbels MJJ, Gerdes N, de Winther MPJ, Lutgens E. Macrophage CD40 plays a minor role in obesity-induced metabolic dysfunction. *PLoS One*. 2018;13:e0202150. (IF: 2,766)
2. Ameti R, Melgrati S, Radice E, Cameroni E, Hub E, Thelen S, Rot A, Thelen M. Characterization of a chimeric chemokine as a specific ligand for ACKR3. *J Leukoc Biol*. 2018;104:391-400. (IF: 4,224)
3. Atzler D, de Winther MPJ. DARC matter(s) for inflammatory cells. *Cardiovasc Res*. 2018;114:e11-e13. (IF: 6,290)
4. Baardman J, Verberk SGS, Prange KHM, van Weeghel M, van der Velden S, Ryan DG, Wüst RCI, Neele AE, Speijer D, Denis SW, Witte ME, Houtkooper RH, O'Neill LA, Knatko EV, Dinkova-Kostova AT, Lutgens E, de Winther MPJ, Van den Bossche J. A defective pentose phosphate pathway reduces inflammatory macrophage responses during hypercholesterolemia. *Cell Rep*. 2018;25:2044-2052.e5. (IF: 8,032)
5. Baaten CCFMJ, Meacham S, de Witt SM, Feijge MAH, Adams DJ, Akkerman JN, Cosemans JMEM, Grassi L, Jupe S, Kostadima M, Mattheij NJA, Prins MH, Ramirez-Solis R, Soehnlein O, Swieringa F, Weber C, White JK, Ouwehand WH, Heemskerk JWM. A synthesis approach of mouse studies to identify genes and proteins in arterial thrombosis and bleeding. *Blood*. 2018;132:e35-e46. (IF: 15,132)
6. Bahls M, Atzler D, Markus MRP, Friedrich N, Böger RH, Völzke H, Felix SB, Schwedhelm E, Dörr M. Low-Circulating homoarginine is associated with dilatation and decreased function of the left ventricle in the general population. *Biomolecules*. 2018;8:e63. (IF: 5,83)
7. Baldassarri F, Schwedhelm E, Atzler D, Böger RH, Cordts K, Haller B, Pressler A, Müller S, Suchy C, Wachter R, Dünken HD, Hasenfuss G, Pieske B, Halle M, Edelmann F, Duvinage A. Relationship between exercise intervention and NO pathway in patients with heart failure with preserved ejection fraction. *Biomarkers*. 2018;23:540-550. (IF: 1,976)
8. Braza MS, van Leent MMT, Lameijer M, Sanchez-Gaytan BL, Arts RJW, Pérez-Medina C, Conde P, Garcia MR, Gonzalez-Perez M, Brahmachary M, Fay F, Kluza E, Kossatz S, Dress RJ, Salem F, Rialdi A, Reiner T, Boros P, Strijkers GJ, Calcagno CC, Ginhoux F, Marazzi I, Lutgens E, Nicolaes GAF, Weber C, Swirski FK, Nahrendorf M, Fisher EA, Duivenvoorden R, Fayad ZA, Netea MG, Mulder WJM, Ochando J. Inhibiting inflammation with myeloid cell-specific nanobiologics promotes organ transplant acceptance. *Immunity*. 2018;49:819-828.e6. (IF: 19,734)
9. Busygina K, Jamasbi J, Seiler T, Deckmyn H, Weber C, Brandl R, Lorenz R, Siess W. Oral bruton tyrosine kinase inhibitors selectively block atherosclerotic plaque-triggered thrombus formation. *Blood*. 2018;131:2605-2616 (IF: 15,132)
10. Caporali A, Bäck M, Daemen MJ, Hoefler IE, Jones EA, Lutgens E, Matter CM, Bochaton-Piallat ML, Siekmann AF, Sluimer JC, Steffens S, Tuñón J, Vindis C, Wentzel JJ, Ylä-Herttuala S, Evans PC. Future directions for therapeutic strategies in post-ischaemic vascularization: a position paper from European Society of Cardiology Working group on Atherosclerosis And Vascular Biology. *Cardiovasc Res*. 2018;114:1411-1421. (IF: 6,290)
11. Casanova-Acebes M, Nicolás-Ávila JA, Li JL, García-Silva S, Balachander A, Rubio-Ponce A, Weiss LA, Adrover JM, Burrows K, A-González N, Ballesteros I, Devi S, Quintana JA, Crainiciuc G, Leiva M, Gunzer M, Weber C, Nagasawa T, Soehnlein O, Merad M, Mortha A, Ng LG, Peinado H, Hidalgo A. Neutrophils instruct homeostatic and pathological states in naive tissues. *J Exp Med*. 2018;215:2778-2795. (IF: 10,790)
12. Chevre R, Silvestre-Roig C, Soehnlein O. Nutritional Modulation of Innate Immunity: The fat-bile-gut connection. *Trends Endocrinol Metab*. 2018;29:686-698. (IF: 10,769)
13. Curaj A, Wu Z, van Zandvoort M, Gresch O, Weber C, Lammers T, Liehn EA, Kiessling F. Molecular ultrasound imaging of the junctional adhesion molecule-A depicts acute changes in blood flow and its effect on endothelial activation. *Arterioscler. Thromb. Vasc. Biol*. 2018;38:40-48. (IF: 6,086)
14. Daugherty A, Lu HS, Hegele RA, Mackman N, Rader DJ, Schmidt AM, Weber C. Response by Daugherty et al to Letter regarding article, "Consideration of sex differences in design and reporting of experimental arterial pathology studies: a statement from the Arterio-sclerosis, Thrombosis, and Vascular Biology Council". *Arterioscler Thromb Vasc Biol*. 2018;38:e101-e102. (IF: 6,086)
15. den Harder AM, de Jong PA, de Groot MCH, Wolterink JM, Budde RPJ, Išgum I, van Solinge WW, Ten Berg MJ, Lutgens E, Veldhuis WB, Haitjema S, Hoefler IE, Leiner T. Commonly available hematological biomarkers are associated with the extent of coronary calcifications. *Atherosclerosis*. 2018;275:166-173. (IF: 4,467)
16. Dickhout A, Koenen RR. Extracellular Vesicles as Biomarkers in Cardiovascular Disease; Chances and Risks. *Front Cardiovasc Med*. 2018;5:113 (IF: 0,500)
17. Di Francesco A, Fedrigo M, Santovito D, Natarelli L, Castellani C, De Pascale F, Toscano G, Fraiese A, Feltrin G, Benazzi E, Nocco A, Thiene G, Valente M, Valle G, Schober A, Gerosa G, Angelini A. MicroRNA signatures in cardiac biopsies and detection of allograft rejection. *J Heart Lung Transplant*. 2018;37:1329-1340. (IF: 7,955)
18. Domschke G, Linden F, Pawig L, Hafner A, Akhavanpoor M, Reymann J, Doesch AO, Erbel C, Weber C, Katus HA, Noels H, Erfle H, Gleissner CA, Runz H. Systematic RNA-interference in primary human monocyte-derived macrophages: A high-throughput platform to study foam cell formation. *Sci Rep*. 2018;8:10516. (IF: 4,122)
19. Döring Y, van der Vorst EPC. Gouty offense in patients with obstructive coronary artery disease despite state-of-the-art therapy. *J Am Heart Assoc*. 2018;7:e010322. (IF: 4,450)
20. Dorn T, Kornherr J, Parrotta EI, Zawada D, Ayetey H, Santamaria G, Iop L, Mastantuono E, Sinnecker D, Goedel A, Dirschingner RJ, My I, Laue S, Bozoglu T, Baarlink C, Ziegler T, Graf E, Hinkel R, Cuda G, Kääh S, Grace AA, Grosse R, Kupatt C, Meitinger T, Smith AG, Laugwitz KL, Moretti A. Interplay of cell-cell contacts and RhoA/MRTF-A signaling regulates cardiomyocyte identity. *EMBO J*. 2018;37:e98133. (IF: 10,557)
21. Eikendal ALM, Bots ML, Gohar A, Lutgens E, Hoefler IE, den Ruijter HM, Leiner T. Circulating levels of P-selectin and E-selectin relate to cardiovascular magnetic resonance-derived aortic characteristics in young adults from the general population, a cross-sectional study. *J Cardiovasc Magn Reson*. 2018;20:54. (IF: 1,438)

22. Evrard M, Kwok IWH, Chong SZ, Teng KWW, Becht E, Chen J, Sieow JL, Penny HL, Ching GC, Devi S, Adrover JM, Li JLY, Liong KH, Tan L, Poon Z, Foo S, Chua JW, Su IH, Balabanian K, Bachelier F, Biswas SK, Larbi A, Hwang WYK, Madan V, Koeffler HP, Wong SC, Newell EW, Hidalgo A, Ginhoux F, Ng LG. Developmental analysis of bone marrow neutrophils reveals populations specialized in expansion, trafficking, and effector functions. *Immunity*. 2018;48:364-379. (IF: 19,734)
23. Faller KME, Atzler D, McAndrew DJ, Zervou S, Whittington HJ, Simon JN, Aksentijevic D, Hove MT, Choe CU, Isbrandt D, Casadei B, Schneider JE, Neubauer S, Lygate CA. Impaired cardiac contractile function in AGAT knockout mice devoid of creatine is rescued by homoarginine but not creatine. *Cardiovasc Res*. 2018;114:417-430. (IF: 6,290)
24. Girbl T, Lenn T, Perez L, Rolas L, Barkaway A, Thiriot A, Del Fresno C, Lynam E, Hub E, Thelen M, Graham G, Alon R, Sancho D, von Andrian UH, Voisin MB, Rot A, Nourshargh S. Distinct Compartmentalization of the Chemokines CXCL1 and CXCL2 and the Atypical Receptor ACKR1 Determine Discrete Stages of Neutrophil Diapedesis. *Immunity*. 2018;49:1062-1076. (IF: 19,734)
25. Gómez-Moreno D, Adrover JM, Hidalgo A. Neutrophils as effectors of vascular inflammation. *Eur J Clin Invest*. 2018;48:e12940. (IF: 3,086)
26. Hinkel R, Klett K, Bähr A, Kupatt C. Thymosin  $\beta$ 4-mediated protective effects in the heart. *Expert Opin Biol Ther*. 2018;18:121-129. (IF: 3,974)
27. Hoogeveen RM, Nahrendorf M, Riksen NP, Netea MG, de Winther MPJ, Lutgens E, Nordestgaard B, Neidhart M, Stroes ESG, Catapano AL, Bekkering S. Monocyte and haematopoietic progenitor reprogramming as common mechanism underlying chronic inflammatory and cardiovascular diseases. *Eur Heart J*. 2018;39:3521-3527. (IF: 23,425)
28. Horckmans M, Bianchini M, Santovito D, Megens RTA, Springael JY, Negri I, Vacca M, Di Eusanio M, Moschetta A, Weber C, Duchene J, Steffens S. Pericardial adipose tissue regulates granulopoiesis, fibrosis and cardiac function after myocardial infarction. *Circulation*. 2018;137:948-960. (IF: 18,881)
29. Jagschies L, Hirschvogel M, Matallo J, Maier A, Mild K, Brunner H, Hinkel R, Gee MW, Radermacher P, Wildhirt SM, Hafner S. Individualized biventricular epicardial augmentation technology in a drug-induced porcine failing heart model. *ASAIO J*. 2018;64:480-488 (IF: 1,842)
30. Kuipers EN, Kantae V, Maarse BCE, van den Berg SM, van Eenige R, Nahon KJ, Reifel-Miller A, Coskun T, de Winther MPJ, Lutgens E, Kooijman S, Harms AC, Hankemeier T, van der Stelt M, Rensen PCN, Boon MR. High Fat Diet Increases Circulating Endocannabinoids Accompanied by Increased Synthesis Enzymes in Adipose Tissue. *Front Physiol*. 2018;9:1913 (IF 3,201)
31. Kusters P, Lutgens E, Seijkens TTP. Exploring immune checkpoints as potential therapeutic targets in atherosclerosis. *Cardiovasc Res*. 2018;114:368-377. (IF: 6,290)
32. Lameijer M, Binderup T, van Leent MMT, Senders ML, Fay F, Malkus J, Sanchez-Gaytan BL, Teunissen AJP, Karakatsanis N, Robson P, Zhou X, Ye Y, Wojtkiewicz G, Tang J, Seijkens TPP, Stroes ESG, Kjaer A, Ochando J, Reiner T, Pérez-Medina C, Cal-cagno C, Fischer EA, Zhang B, Temel RE, Swirski FK, Nahrendorf M, Fayad ZA, Lutgens E, Mulder WJM, Duivenvoorden R. Efficacy and safety assessment of a TRAF6-targeted nanoimmunotherapy in atherosclerotic mice and non-human primates. *Nat. Biomed. Eng*. 2018;2:279-292. (IF: 1,000)
33. Längin M, Mayr T, Reichart B, Michel S, Buchholz S, Guethoff S, Dashkevich A, Baehr A, Egerer S, Bauer A, Mihalj M, Panelli A, Issl L, Ying J, Fresch AK, Buttgerit I, Mokelke M, Radan J, Werner F, Lutzmann I, Steen S, Sjöberg T, Paskevicius A, Qiuming L, Sfriso R, Rieben R, Dahlhoff M, Kessler B, Kemter E, Klett K, Hinkel R, Kupatt C, Falkenau A, Reu S, Ellgass R, Herzog R, Binder U, Wich G, Skerra A, Ayares D, Kind A, Schönmann U, Kaup FJ, Hagl C, Wolf E, Klymiuk N, Brenner P, Abicht JM. Consistent success in life-supporting porcine cardiac xenotransplantation. *Nature*. 2018;564:430-433. (IF: 41,577)
34. Leoni G, Soehnlein O. (Re) Solving Repair After Myocardial Infarction. *Front Pharmacol*. 2018;9:1342. (IF: 3,831)
35. Lu HS, Schmidt AM, Hegele RA, Mackman N, Rader DJ, Weber C, Daugherty A. Reporting sex and sex differences in preclinical studies. *Arterioscler Thromb Vasc Biol*. 2018;38:e171-e184. (IF: 6,086)
36. Maas SL, Soehnlein O and Viola JR. Organ-specific mechanisms of transendothelial neutrophil migration in the lung, liver, kidney, and aorta. *Front Immunol*. 2018;9:2739. (IF: 5,511)
37. Mederos Y, Schnitzler M, Gudermann T, Storch U. Emerging Roles of Diacylglycerol-Sensitive TRPC4/5 Channels Cells. 2018 Nov 20;7(11). (IF: 36,216)
38. Natarelli L, Geißler C, Csaba G, Wei Y, Zhu M, di Francesco A, Hartmann P, Zimmer R, Schober A. miR-103 promotes endothelial maladaptation by targeting IncWDR59. *Nat Commun*. 2018;9:2645. (IF: 12,353)
39. Neele AE, de Winther MPJ. Repressing the repressor: Ezh2 mediates macrophage activation. *J Exp Med*. 2018;275:156-165. (IF: 10,790)
40. Neele AE, Gijbels MJJ, van der Velden S, Hoeksema MA, Boshuizen MCS, Prange KHM, Chen HJ, Van den Bossche J, van Roomen CPPA, Shami A, Levels JHM, Kroon J, Lucas T, Dimmeler S, Lutgens E, de Winther MPJ. Myeloid Kdm6b deficiency results in advanced atherosclerosis. *Atherosclerosis*. 2018;275:156-165. (IF: 4,467)
41. Nicolás-Ávila JA, Hidalgo A, Ballesteros I. Specialized functions of resident macrophages in brain and heart. *J Leukoc Biol*. 2018;104:743-756. (IF: 4,224)
42. Niekamp C, Atzler D, Ojeda FM, Sinning CR, Lackner KJ, Böger RH, Munzel T, Beutel ME, Schmidtman I, Pfeiffer N, Leuschner A, Blankenberg S, Wild PS, Zeller T, Schwedhelm E, Schnabel RB. Cross-sectional associations between homoarginine, intermediate phenotypes, and atrial fibrillation in the community - The Gutenberg Health Study. *Biomolecules*. 2018;8:e86. (IF: 2,656)
43. Pacher P, Steffens S, Haskó G, Schindler TH, Kunos Cardiovascular effects of marijuana and synthetic cannabinoids: the good, the bad, and the ugly. *Nat Rev Cardiol*. 2018;15:151-166. (IF: 15,162)
44. Patel J, Lutgens E. Scientists on the Spot: Esther Lutgens on the immune system and atherosclerosis. *Cardiovasc Res*. 2018;114:e113. (IF: 6,290)
45. Paulin N, Viola JR, Maas SL, de Jong R, Fernandes-Alnemri T, Weber C, Drechsler M, Döring Y, Soehnlein Double-Strand DNA sensing Aim2 inflammasome regulates atherosclerotic plaque vulnerability. *Circulation*. 2018;138:321-323. (IF: 18,881)

46. Pfeiler S, Gerdes N. Atherosclerosis: cell biology and lipoproteins - focus on anti-inflammatory therapies. *Curr Opin Lipidol.* 2018;29:53-55. (IF: 3,853)
47. Pircher J, Czermak T, Ehrlich A, Eberle C, Gaitzsch E, Margraf A, Grommes J, Saha P, Titova A, Ishikawa Ankerhold H, Stark K, Petzold T, Stocker T, Weckbach LT, Novotny J, Sperandio M, Nieswandt B, Smith A, Mannell H, Walzog B, Horst D, Soehnlein O, Massberg S, Schulz C. Cathelicidins prime platelets to mediate arterial thrombosis and tissue inflammation. *Nat Commun.* 2018;9:1523. (IF: 12,353)
48. Poller W, Dimmeler S, Heymans S, Zeller T, Haas J, Karakas M, Leistner DM, Jakob P, Nakagawa S, Blankenberg S, Engelhardt S, Thum T, Weber C, Meder B, Hajjar R, Landmesser U. Non-coding RNAs in cardiovascular diseases: diagnostic and therapeutic perspectives. *Eur Heart J.* 2018;39:2704-216. (IF: 23,425)
49. Rami M, Guillaumat-Prats R, Rinne P, Salvermoser M, Ring L, Bianchini M, Blanchet X, Megens RTA, Döring Y, Walzog B, Soehnlein O, Weber C, Faussner A, Steffens S. Chronic intake of the selective serotonin reuptake inhibitor fluoxetine enhances atherosclerosis. *Arterioscler Thromb Vasc Biol.* 2018;38:1007-1019. (IF: 6,086)
50. Renz BW, Takahashi R, Tanaka T, Macchini M, Hayakawa Y, Dantes Z, Maurer HC, Chen X, Jiang Z, Westphalen CB, Ilmer M, Valenti G, Mohanta SK, Habenicht AJR, Middelhoff M, Chu T, Nagar K, Tailor Y, Casadei R, Di Marco M, Kleespies A, Friedman RA, Remotti H, Reichert M, Worthley DL, Neumann J, Werner J, Iuga AC, Olive KP, Wang TC.  $\beta$ 2 Adrenergic-neurotrophin feedforward loop promotes pancreatic cancer. *Cancer Cell.* 2018;33:75-90. (IF: 22,844)
51. Rinne P, Guillaumat-Prats R, Rami M, Bindila L, Ring L, Lyytikäinen LP, Raitoharju E, Oksala N, Lehtimäki T, Weber C, van der Vorst EPC, Steffens S. Palmitoylethanolamide promotes a proresolving macrophage phenotype and attenuates atherosclerotic plaque formation. *Arterioscler Thromb Vasc Biol.* 2018;38:2562-2575. (IF: 6,086)
52. Rinne P, Kadiri JJ, Velasco-Delgado M, Nuutinen S, Viitala M, Hollmén M, Rami M, Savontaus E, Steffens S. Melanocortin 1 receptor deficiency promotes atherosclerosis in apolipoprotein E<sup>-/-</sup> Mice. *Arterioscler Thromb Vasc Biol.* 2018;38:313-323. (IF: 6,086)
53. Rouwet E, Lutgens E. 2016 Jeffrey M. Hoeg award lecture: immune checkpoints in atherosclerosis: toward immunotherapy for atheroprotection. *Arterioscler Thromb Vasc Biol.* 2018;38:1678-1688. (IF: 6,086)
54. Salas-Perdomo A, Miró-Mur F, Urra X, Justicia C, Gallizioli M, Zhao Y, Brait VH, Laredo C, Tudela R, Hidalgo A, Chamorro Á, Planas AM. T cells prevent hemorrhagic transformation in ischemic stroke by P-selectin binding. *Arterioscler Thromb Vasc Biol.* 2018;38:1761-1771. (IF: 6,086)
55. Salvermoser M, Pick R, Weckbach LT, Zehrer A, Löhner P, Drechsler M, Sperandio M, Soehnlein O, Walzog B. Myosin 1f is specifically required for neutrophil migration in 3D environments during acute inflammation. *Blood.* 2018;131:1887-1898. (IF: 15,132)
56. Schmitz C, Noels H, El Bounkari O, Strausfeld E, Megens RTA, Sternkopf M, Alampour-Rajabi S, Krammer C, Tilstam PV, Gerdes N, Bürger C, Karpuniotu A, Bucala R, Jankowski J, Weber C, Bernhagen J. Mif-deficiency favors an atheroprotective autoantibody phenotype in atherosclerosis. *FASEB J.* 2018;32:4428-4443. (IF: 5,595)
57. Schönhoff M, Weineck G, Hoppe J, Hornig S, Cordts K, Atzler D, Gerloff C, Böger R, Neu A, Schwedhelm E, Choe CU. Cognitive performance of 20 healthy humans supplemented with L-homoarginine for 4 weeks. *Clin Neurosci.* 2018;50:237-241 (IF: 1,64)
58. Schumski A, Winter C, Döring Y, Soehnlein O. The ins and outs of myeloid cells in atherosclerosis. *J Innate Immun.* 2018;10:479-486. (IF: 3,837)
59. Seijkens TTP, Lutgens E. Cardiovascular oncology: exploring the effects of targeted cancer therapies on atherosclerosis. *Curr Opin Lipidol.* 2018;29:381-388. (IF: 3,853)
60. Seijkens TTP, van Tiel CM, Kusters PJH, Atzler D, Soehnlein O, Zarzycka B, Aarts SABM, Lameijer M, Gijbels MJ, Beckers L, den Toom M, Slütter B, Kuiper J, Duchene J, Aslani M, Megens RTA, van 't Veer C, Kooij G, Schrijver R, Hoeksema MA, Boon L, Fay F, Tang J, Baxter S, Jongejan A, Moerland PD, Vriend G, Bleijlevens B, Fisher EA, Duivenvoorden R, Gerdes N, de Winther MPJ, Nicolaes GA, Mulder WJM, Weber C, Lutgens E. Targeting CD40-induced TRAF6 signaling in macrophages reduces atherosclerosis. *J Am Coll Cardiol.* 2018;71:527-542. (IF: 16,834)
61. Soehnlein O, Bazioti V, Westerterp M. A Pad 4 plaque erosion. *Circ Res.* 2018;123:6-8. (IF: 15,211)
62. Soehnlein O. Atherothrombosis : novel therapeutic strategies. *Herz.* 2018;43:103-108. (IF: 0,936)
63. Soehnlein O. Decision shaping neutrophil-platelet interplay in inflammation: from physiology to intervention. *Eur J Clin Invest.* 2018;48. (IF: 3,086)
64. Steven S, Dib M, Hausding M, Kashani F, Oelze M, Kröller-Schön S, Hanf A, Daub S, Roohani S, Gramlich Y, Lutgens E, Schulz E, Becker C, Lackner KJ, Kleinert H, Knosalla C, Niesler B, Wild PS, Münzel T, Daiber A. CD40L controls obesity-associated vascular inflammation, oxidative stress and endothelial dysfunction in mice - translational aspects for man. *Car-diovasc Res.* 2018;114:312-323. (IF: 6,290)
65. Stocker TJ, Pircher J, Skenderi A, Ehrlich A, Eberle C, Megens RTA, Petzold T, Zhang Z, Walzog B, Müller-Taubenberger A, Weber C, Massberg S, Ishikawa-Ankerhold H, Schulz C. The actin regulator Coronin-1A modulates platelet shape change and consolidates arterial thrombosis. *Thromb Haemost.* 2018;118:2098-2111. (IF: 6,086)
66. Trevino-Villarreal JH, Reynolds JS, Bartelt A, Langston PK, MacArthur MR, Arduini A, Tosti V, Veronese N, Bertozzi B, Brace LE, Mejia P, Trocha K, Kajitani GS, Longchamp A, Harputlugil E, Gathungu R, Bird SS, Bullock AD, Figenschau RS, Andriole GL, Thompson A, Heeren J, Ozaki CK, Kristal BS, Fontana L, Mitchell JR. Dietary protein restriction reduces circulating VLDL triglyceride levels via CREBH-APOA5-dependent and -independent mechanisms. *JCI Insight.* 2018;3 (IF: 6,014)
67. Tuñón J, Bäck M, Badimón L, Bochaton-Piallat ML, Cariou B, Daemen MJ, Egido J, Evans PC, Francis SE, Ketelhuth DF, Lutgens E, Matter CM, Monaco C, Steffens S, Stroes E, Vindis C, Weber C, Hoefler IE; ESC Working Group on Atherosclerosis and Vascular Biology. Interplay between hypercholesterolaemia and inflammation in atherosclerosis: Translating experimental targets into clinical practice. *Eur J Prev Cardiol.* 2018;25:948-955. (IF: 4,542)
68. Vajen T, Koenen RR, Werner I, Staudt M, Projahn D, Curaj A, Sönmez TT, Simsekilmaz S, Schumacher D, Möllmann J, Hackeng TM, Hundelshausen PV, Weber C, Liehn EA. Blocking CCL5-CXCL4 heteromerization preserves heart function after myocardial infarction by attenuating leukocyte recruitment and NETosis. *Sci Rep.* 2018;8:10647. (IF: 4,122)

69. van der Tuin SJL, Li Z, Berbée JFP, Verkouter I, Ringnalda LE, Neele AE, van Klinken JB, Rensen SS, Fu J, de Winther MPJ, Groen AK, Rensen PCN, Wil-lems van Dijk K, Wang Y. Lipopolysaccharide lowers cholesteryl ester transfer protein by activating F4/80+Clec4f+Vsig4+Ly6C- kupffer cell subsets. *J Am Heart Assoc.* 2018;7:e008105. (IF: 4,450)
70. van der Vorst EPC, de Jong RJ, Donners MMPC. Message in a microbottle: modulation of vascular inflammation and atherosclerosis by extracellular vesicles. *Front Cardiovasc Med.* 2018;22:5-2. (IF: 3,075)
71. van der Vorst EPC, Döring Y. Resistin keeps its Janus face. *Int J Cardiol.* 2018;272:47-48. (IF: 4,034)
72. van der Vorst EPC, Weber C, Donners MMPC. A disintegrin and metalloproteases (ADAMs) in cardiovascular, metabolic and inflammatory diseases: aspects for theranostic approaches. *Thromb Haemost.* 2018;118:1167-1175. (IF: 4,952)
73. van der Vorst EPC, Weber C. Metabolomic profiling of atherosclerotic plaques: towards improved cardiovascular risk stratification. *Eur Heart J.* 2018;39:2311-2313. (IF: 23,425)
74. Vinketova K, Karagoyozov I, Koleva V, Hristov M, Mourdjeva M, Sperandio M, Oreshkova T. Progesterone and cyclic adenosine monophosphate down-regulate CD90 in the stromal cells of human decidua. In vitro evidence and in situ findings. *Am J Reprod Immunol.* 2018 Nov;80(5):e13043. (IF: 1,55)
75. Viola JR, Lemnitzer P, Paulin N, Drechsler M, Nazari-Jahantigh M, Maas S, De Jong RJ, Winter J, Schober A, Weber C, Atabai K, Soehnlein O. Deletion of MFGE8 inhibits neointima formation upon arterial damage. *Thromb Haemost.* 2018;118:1340-1342. (IF: 4,952)
76. Wang W, Liu W, Fidler T, Wang Y, Tang Y, Woods B, Welch C, Cai B, Silvestre-Roig C, Ai D, Yang YG, Hidalgo A, Soehnlein O, Tabas I, Levine RL, Tall AR, Wang N. Macrophage inflammation, erythrophagocytosis, and accelerated atherosclerosis in Jak2 V617F mice. *Circ Res.* 2018;123:e35-e47. (IF: 15,211)
77. Wei Y, Corbalán-Campos J, Gurung R, Natarelli L, Zhu M, Exner N, Erhard F, Greulich F, Geißler C, Uhlenhaut NH, Zimmer R, Schober A. Dicer in macrophages prevents atherosclerosis by promoting mitochondrial oxidative metabolism. *Circulation* 2018;138: 2007-2020. (IF: 18,881)
78. Wei Y, Zhu M, Schober A. Macrophage microRNAs as therapeutic targets for atherosclerosis, metabolic syndrome, and cancer. *Int J Mol Sci.* 2018;19:e1756. (IF: 3,687)
79. Williams JW, Martel C, Potteaux S, Esaulova E, Ingersoll MA, Elvington A, Saunders BT, Huang LH, Habenicht AJ, Zinselmeyer BH, Randolph GJ. Limited macrophage positional dynamics in progressing or re-progressing murine atherosclerotic plaques. *Arterioscler Thromb Vasc Biol.* 2018;38:1702-1710. (IF: 6,086)
80. Winter C, Silvestre-Roig C, Ortega-Gomez A, Lemnitzer P, Poelman H, Schumski A, Winter J, Drechsler M, de Jong R, Immler R, Sperandio M, Hristov M, Zeller T, Nicolaes GAF, Weber C, Viola JR, Hidalgo A, Scheiermann C, Soehnlein O. Chrono-pharmacological targeting of the CCL2-CCR2 axis ameliorates atherosclerosis. *Cell Metab.* 2018;28:175-182.e5. (IF: 20,565)
81. Winter C, Soehnlein O, Maegdefessel L. TIMP1 in the aorta: smooth muscle cell-specific deletion of BMAL1 limits murine abdominal aortic aneurysm development. *Arterioscler Thromb Vasc Biol.* 2018;38:982-983. (IF: 6,086)
82. Winter C, Soehnlein O. The potential of chronopharmacology for treatment of atherosclerosis. *Curr Opin Lipidol.* 2018;29:368-374. (IF: 3,853)
83. Zhou Z, Schober A, Nazari-Jahantigh M. Dicer promotes endothelial recovery and limits lesion formation after vascular injury through miR-126-5p. *Int J Cardiol.* 2018;273:199-202. (IF: 4,034)
84. Ziegler T, Bähr A, Howe A, Klett K, Husada W, Weber C, Laugwitz KL, Kupatt C, Hinkel R. Tβ4 increases neovascularization and cardiac function in chronic myocardial ischemia of normo- and hypercholesterolemic pigs. *Mol Ther.* 2018;26:1706-1714. (IF: 7,008)
85. Ziegler T, Hinkel R, Kupatt C. Induced pluripotent stem cell derived cardiac models: effects of thymosin β4. *Exp Opin Biol Ther.* 2018;18:111-120. (IF: 3,974)
86. Ziegler T, Kraus M, Husada W, Gesenhues F, Jiang Q, Pinkenburg O, Trenkwalder T, Laugwitz KL, le Noble F, Weber C, Kupatt C, Hinkel R. Steerable induction of the thymosin β4/MRTF-A pathway via AAV-based overexpression induces therapeutic neovascularization. *Hum Gene Ther.* 2018;28:1407-1415. (IF: 4,241)